Sera Prognostics, Inc.· SERA
🇺🇸 US · MicroBroad USNASDAQ
- Price
- $2.01
- Day
- -0.50%
- Mkt Cap
- $76.76M
- 52W Range
- $1.56 – $3.95
- Volume
- 64.1K
- Beta
- 0.98
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Dr. Thaïs Aliabadi, a board-certified OB-GYN and co-host of the SHE MD podcast, makes the case that preterm birth risk is personal, knowable between weeks 18 and 21 of pregnancy, and worth a direct conversation with your doctor. She points to a simple blood test, the PreTRM® Test from Sera Prognostics, and PRIME trial results showing early, low-cost intervention can cut the earliest preterm births by more than half.
Read full article
SALT LAKE CITY, Aug. 19, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced today that Scott Gleason has been appointed Chief Financial Officer (CFO), effective August 31, 2026. Mr. Gleason brings more than 25 years of healthcare, diagnostics, and capital markets experience to Sera.
Read full article